Literature DB >> 24196912

Perventricular closure of perimembranous ventricular septal defects using the concentric occluder device.

Shunmin Wang1, Zhongyun Zhuang, Haibo Zhang, Jinhao Zhen, Yanan Lu, Jinfen Liu, Zhiwei Xu.   

Abstract

This report summarizes the authors' clinical experience with perventricular closure of the perimembranous ventricular septal defect (PmVSD) using the concentric occluder as a minimally invasive technique without cardiopulmonary bypass and following transesophageal echocardiography (TEE) guidance. Between July 2011 and March 2013, 61 patients with PmVSD underwent perventricular concentric device closure using a minimally invasive inferior sternotomy approach. The basal diameter of the PmVSD ranged from 2.5 to 7 mm. The diameter of the occlusion device waist ranged from 4 to 8 mm. A ventricular septal aneurysm or an adhesive tricuspid valve was present in 49 patients. Multiple orifices in the aneurysm were treated in ten patients, including dispersed orifices in four patients and comparatively concentrated orifices in the remaining six patients. The occlusion devices were deployed via the right ventricle with TEE guidance and no cardiopulmonary bypass. Complete shunt occlusion was achieved for all the patients in the operating room. The orifices of the ventricular septal aneurysm were closed in 46 patients, with the left disc of the concentric devices placed in the aneurysms, whereas the PmVSDs in the remaining 15 patients were closed from the ventricular septal defect (VSD) basal part following the rule that the upper rim of the PmVSD be more than 2 mm from the aortic valve. Ventricular premature beats occurred in one patient. The follow-up period ranged from 1 to 21 months (median 13.5 ± 8.2 months), and the patients had stable heart function postoperatively. None of the patients had more than mild valvular regurgitation, and no worsening regurgitation was observed in those who had tricuspid or aortic regurgitation before surgery. No complete atrioventricular block, position shift of the occlusion devices, thrombosis, or residual VSD occurred during the follow-up period. The perventricular concentric device closure of PmVSD with an inferior sternotomy in selected patients is a safe, feasible, and simple treatment. The concentric device is easier to anchor than the eccentric device and has proved to be a reasonable choice for PmVSD occlusion, especially in patients with a perimembranous aneurysm formation or PmVSD extending to the inflow tract.

Entities:  

Mesh:

Year:  2013        PMID: 24196912     DOI: 10.1007/s00246-013-0823-0

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  15 in total

1.  Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: results of the U.S. phase I trial.

Authors:  Yun-Ching Fu; John Bass; Zahid Amin; Wolfgang Radtke; John P Cheatham; William E Hellenbrand; David Balzer; Qi-Ling Cao; Ziyad M Hijazi
Journal:  J Am Coll Cardiol       Date:  2006-01-17       Impact factor: 24.094

2.  Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: multicenter follow-up study.

Authors:  J Masura; W Gao; P Gavora; K Sun; A Q Zhou; S Jiang; L Ting-Liang; Y Wang
Journal:  Pediatr Cardiol       Date:  2005 May-Jun       Impact factor: 1.655

3.  Minimally invasive perventricular device closure of perimembranous ventricular septal defect without cardiopulmonary bypass: multicenter experience and mid-term follow-up.

Authors:  Quansheng Xing; Silin Pan; Qi An; Zewei Zhang; Jianhua Li; Feng Li; Qin Wu; Zhongyun Zhuang
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-03       Impact factor: 5.209

4.  Transcatheter closure of perimembranous ventricular septal defects using the amplatzer membranous VSD occluder: immediate and midterm results of an international registry.

Authors:  Ralf Holzer; Jo de Giovanni; Kevin P Walsh; Andrew Tometzki; Th Goh; Fakhri Hakim; Carlos Zabal; Jose Suarez de Lezo; Qi-Ling Cao; Ziyad M Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2006-10       Impact factor: 2.692

5.  Perventricular device closure of perimembranous ventricular septal defects in 61 young children: early and midterm follow-up results.

Authors:  Kaiyu Tao; Ke Lin; Yingkang Shi; Haibo Song; Raphael C Lui; Changping Gan; Qi An
Journal:  J Thorac Cardiovasc Surg       Date:  2010-06-18       Impact factor: 5.209

6.  Heart block and empirical therapy after transcatheter closure of perimembranous ventricular septal defect.

Authors:  William C L Yip; Frank Zimmerman; Ziyad M Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2005-11       Impact factor: 2.692

7.  Atrioventricular block after transcatheter closure of perimembranous ventricular septal defects.

Authors:  M A Walsh; J Bialkowski; M Szkutnik; M Pawelec-Wojtalik; W Bobkowski; K P Walsh
Journal:  Heart       Date:  2006-01-31       Impact factor: 5.994

8.  Early surgical removal of membranous ventricular septal device might allow recovery of atrio-ventricular block.

Authors:  Caroline Ovaert; Andreea Dragulescu; Thierry Sluysmans; Mario Carminati; Alain Fraisse
Journal:  Pediatr Cardiol       Date:  2007-11-17       Impact factor: 1.655

9.  Complete heart block associated with device closure of perimembranous ventricular septal defects.

Authors:  Dragos Predescu; Rajiv R Chaturvedi; Mark K Friedberg; Lee N Benson; Akira Ozawa; Kyong-Jin Lee
Journal:  J Thorac Cardiovasc Surg       Date:  2008-06-06       Impact factor: 5.209

10.  Minimally invasive perventricular device closure of an isolated perimembranous ventricular septal defect with a newly designed delivery system: preliminary experience.

Authors:  Xing Quansheng; Pan Silin; Zhuang Zhongyun; Rong Youbao; Li Shengde; Cao Qian; Duan Shuhua; Hou Kefeng; Ji Zhixian; Wu Qin
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03       Impact factor: 5.209

View more
  6 in total

1.  Transcatheter perimembranous ventricular septal defect closure under transthoracic echocardiographic guidance without fluoroscopy.

Authors:  Shouzheng Wang; Wenbin Ouyang; Yao Liu; Fengwen Zhang; Gaili Guo; Guangzhi Zhao; Xiangbin Pan
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Effects of transthoracic device closure on ventricular septal defects and reasons for conversion to open-heart surgery: A meta-analysis.

Authors:  Yang Zhou; Ling-Xi Liu; Fei Zhao; Shi-Hai Tang; Hua-Li Peng; Yun-Han Jiang
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

3.  Health-related quality of life in children and adolescents undergoing intraoperative device closure of isolated perimembranous ventricular septal defects in southeastern China.

Authors:  Jiang-Shan Huang; Shu-Ting Huang; Kai-Peng Sun; Zhi-Nuan Hong; Liang-Wan Chen; Yur-Ren Kuo; Qiang Chen
Journal:  J Cardiothorac Surg       Date:  2019-12-16       Impact factor: 1.637

4.  Minimally invasive closure of transthoracic ventricular septal defect: postoperative complications and risk factors.

Authors:  Chunnian Ren; Chun Wu; Zhengxia Pan; Yonggang Li
Journal:  J Cardiothorac Surg       Date:  2021-03-19       Impact factor: 1.637

Review 5.  What Interventional Cardiologists Are Still Leaving to the Surgeons?

Authors:  Worakan Promphan; Shakeel A Qureshi
Journal:  Front Pediatr       Date:  2016-06-13       Impact factor: 3.418

Review 6.  Recent advances in managing septal defects: ventricular septal defects and atrioventricular septal defects.

Authors:  P Syamasundar Rao; Andrea D Harris
Journal:  F1000Res       Date:  2018-04-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.